The United Kingdom and the United States have secured a important trade agreement that will keep no levies on British medicine shipments entering the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to raise funding on drugs through the National Health Service (NHS). This move ensures that tariffs on these vital products will remain at zero for a period of 36 months.
This agreement is in response to previous threats to hike import taxes on patented pharmaceutical products, with potential rates floated reaching one hundred percent.
"This deal with the UK bolsters the worldwide climate for innovative medicines and establishes much-needed fairness to transatlantic drug exports," an announcement noted.
Economic Significance
Pharmaceuticals are one of the UK's largest export categories to the United States, which is easily the biggest market for major UK drugmakers.
Trade data indicate that in the 12 months leading up to September, the UK sold medicines totaling over eleven billion pounds to the US. This amount made up a significant portion of British export trade in that period.
"This deal secures work, stimulates funding and sets the stage for the UK to establish itself as a global hub for medical research," a government official remarked.
Key NHS Changes
The pact entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to increase total public funding on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments were more than 20%.
Recent Tensions
This agreement comes amid a long-running row between the drug companies and the ministers over medicine costs and regulatory access.
These tensions were heightened by arguments that US consumers were charged a premium for the equivalent treatments than patients in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been delayed or scrapped, while major investments have been pledged toward US facilities.
A senior figure acknowledged that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the past decade.
